Want to see IN:GLAXO full AI Analyst Report?
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) Ratios
7 Followers
GlaxoSmithKline Pharmaceuticals Limited Ratios
IN:GLAXO's free cash flow for Q1 2027 was ₹0.00. For the 2027 fiscal year, IN:GLAXO's free cash flow was increased by ₹0.00 and operating cash flow was ₹0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.03 | 1.79 | 1.84 | 1.88 | 2.18 |
| Quick Ratio | 1.77 | 1.54 | 1.49 | 1.53 | 1.87 |
| Cash Ratio | 0.62 | 0.28 | 0.04 | 0.03 | 0.17 |
| Solvency Ratio | 0.54 | 0.46 | 0.35 | 0.41 | 0.88 |
| Operating Cash Flow Ratio | 0.57 | 0.68 | 0.38 | 0.37 | 0.48 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 47.72 | 11.53 | 13.19 |
| Net Current Asset Value | ₹ 15.50B | ₹ 12.53B | ₹ 10.19B | ₹ 9.09B | ₹ 17.38B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.91 | 2.11 | 2.00 | 1.91 | 1.74 |
| Debt Service Coverage Ratio | 404.82 | 844.19 | 46.75 | 12.78 | 5.43 |
| Interest Coverage Ratio | 461.50 | 944.92 | 756.21 | 684.80 | 580.26 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 2.12 | 0.66 | 1.21 | 1.02 | 1.23 |
| Net Debt to EBITDA | -0.72 | -0.40 | -0.05 | -0.02 | -0.36 |
| Profitability Margins | |||||
| Gross Profit Margin | 43.57% | 60.47% | 60.76% | 59.89% | 57.96% |
| EBIT Margin | 32.97% | 33.85% | 24.29% | 23.02% | 21.32% |
| EBITDA Margin | 38.60% | 35.64% | 25.50% | 24.25% | 22.66% |
| Operating Profit Margin | 32.97% | 29.91% | 39.38% | 38.12% | 35.33% |
| Pretax Profit Margin | 36.79% | 33.81% | 23.63% | 25.72% | 23.77% |
| Net Profit Margin | 27.11% | 24.89% | 17.08% | 18.78% | 51.70% |
| Continuous Operations Profit Margin | 27.11% | 24.89% | 17.08% | 18.69% | 11.62% |
| Net Income Per EBT | 73.68% | 73.62% | 72.28% | 73.01% | 217.54% |
| EBT Per EBIT | 111.60% | 113.06% | 60.00% | 67.48% | 67.26% |
| Return on Assets (ROA) | 23.96% | 22.58% | 16.59% | 18.36% | 36.58% |
| Return on Equity (ROE) | 45.69% | 47.54% | 33.19% | 35.07% | 63.64% |
| Return on Capital Employed (ROCE) | 49.51% | 50.59% | 66.95% | 61.97% | 39.47% |
| Return on Invested Capital (ROIC) | 36.25% | 37.12% | 47.82% | 43.83% | 18.82% |
| Return on Tangible Assets | 24.00% | 22.65% | 16.70% | 18.55% | 36.85% |
| Earnings Yield | 2.68% | 1.96% | 1.75% | 2.71% | 5.68% |
| Efficiency Ratios | |||||
| Receivables Turnover | 12.29 | 10.33 | 9.87 | 9.85 | 15.97 |
| Payables Turnover | 2.49 | 2.08 | 2.17 | 2.09 | 2.38 |
| Inventory Turnover | 3.11 | 3.06 | 2.58 | 2.84 | 2.58 |
| Fixed Asset Turnover | 12.47 | 13.13 | 11.11 | 10.32 | 10.07 |
| Asset Turnover | 0.88 | 0.91 | 0.97 | 0.98 | 0.71 |
| Working Capital Turnover Ratio | 2.29 | 2.68 | 2.83 | 2.05 | 2.29 |
| Cash Conversion Cycle | 0.76 | -20.78 | 9.95 | -9.26 | 11.03 |
| Days of Sales Outstanding | 29.69 | 35.35 | 36.98 | 37.04 | 22.85 |
| Days of Inventory Outstanding | 117.48 | 119.37 | 141.41 | 128.74 | 141.61 |
| Days of Payables Outstanding | 146.41 | 175.50 | 168.44 | 175.04 | 153.43 |
| Operating Cycle | 147.16 | 154.72 | 178.39 | 165.78 | 164.46 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 60.35 | 76.14 | 34.36 | 28.44 | 45.30 |
| Free Cash Flow Per Share | 57.09 | 74.78 | 32.51 | 25.85 | 43.36 |
| Dividend Paid and CapEx Coverage Ratio | 1.33 | 1.67 | 1.02 | 0.31 | 1.50 |
| Capital Expenditure Coverage Ratio | 18.50 | 56.03 | 18.64 | 11.00 | 23.40 |
| Operating Cash Flow Coverage Ratio | 30.73 | 129.64 | 31.18 | 31.16 | 40.38 |
| Operating Cash Flow to Sales Ratio | 0.27 | 0.35 | 0.17 | 0.15 | 0.25 |
| Free Cash Flow Yield | 2.50% | 2.67% | 1.64% | 1.95% | 2.60% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 37.33 | 51.08 | 57.04 | 36.93 | 17.60 |
| Price-to-Sales (P/S) Ratio | 10.12 | 12.72 | 9.74 | 6.94 | 9.10 |
| Price-to-Book (P/B) Ratio | 17.06 | 24.29 | 18.93 | 12.95 | 11.20 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 39.99 | 37.41 | 61.09 | 51.24 | 38.44 |
| Price-to-Operating Cash Flow Ratio | 37.83 | 36.74 | 57.81 | 46.58 | 36.80 |
| Price-to-Earnings Growth (PEG) Ratio | 3.20 | 0.89 | -19.67 | 0.54 | 0.69 |
| Enterprise Value Multiple | 25.49 | 35.29 | 38.16 | 28.58 | 39.81 |
| Enterprise Value | 376.09B | 468.60B | 336.04B | 225.35B | 295.69B |
| EV to EBITDA | 25.49 | 35.29 | 38.16 | 28.58 | 39.81 |
| EV to Sales | 9.84 | 12.58 | 9.73 | 6.93 | 9.02 |
| EV to Free Cash Flow | 38.89 | 36.99 | 61.01 | 51.19 | 38.10 |
| EV to Operating Cash Flow | 36.78 | 36.33 | 57.74 | 46.54 | 36.47 |
| Tangible Book Value Per Share | 133.45 | 114.40 | 103.54 | 100.27 | 146.85 |
| Shareholders’ Equity Per Share | 133.84 | 115.19 | 104.93 | 102.27 | 148.78 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.26 | 0.26 | 0.28 | 0.27 | 0.51 |
| Revenue Per Share | 225.58 | 219.95 | 203.87 | 190.99 | 183.15 |
| Net Income Per Share | 61.15 | 54.76 | 34.83 | 35.87 | 94.69 |
| Tax Burden | 0.74 | 0.74 | 0.72 | 0.73 | 2.18 |
| Interest Burden | 1.12 | 1.00 | 0.97 | 1.12 | 1.11 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.07 | 0.19 | 0.18 | 0.18 | 0.19 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.99 | 1.39 | 0.99 | 0.58 | 0.33 |
Currency in INR
